加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.52
+US$0.14 · +10.14%
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
收盘时
US$1.52
+US$0.14 · +10.14%
盘后
US$1.50
−US$0.02 · -1.32%
10月12日 17:09 ET
盘中时间采用ET。市场数据可能有所延迟。
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
日内区间
当前US$1.52
52周区间
当前US$1.52
盘中时间采用ET。市场数据可能有所延迟。
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
日内区间
当前US$1.52
52周区间
当前US$1.52
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 5.98万 USD | 5.73万 USD | — | — |
| 毛利 | — | −5.98万 USD | −5.73万 USD | — | — |
| 研究与开发 | 1902.58万 USD | 2256.55万 USD | 2776.2万 USD | 2943.1万 USD | 1125.45万 USD |
| 销售、一般及管理费用 | 1251.81万 USD | 1369.59万 USD | 1528.2万 USD | 1224.14万 USD | 1018.48万 USD |
| 营业费用 | 3154.4万 USD | 3626.14万 USD | 4304.5万 USD | 4167.24万 USD | 2143.93万 USD |
| 利息收入 | 121.72万 USD | 251.5万 USD | 290.3万 USD | 93.52万 USD | 4346 USD |
| 利息支出 | 533.86万 USD | 467.3万 USD | 420.6万 USD | 131.7万 USD | — |
| 折旧和摊销 | 2.18万 USD | 2111.2万 USD | 5.73万 USD | 86 USD | 5357 USD |
| 营业利润 | −3154.4万 USD | −3632.12万 USD | −4304.5万 USD | −4167.24万 USD | −2143.93万 USD |
| 净利润 | −3449.55万 USD | −3761.04万 USD | −4294.2万 USD | −4085.49万 USD | −1691.85万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.00
上涨空间 492.11%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
